Austin Health

Title
Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease.
Publication Date
2022-05-26
Author(s)
Vacher, Michael
Doré, Vincent
Porter, Tenielle
Milicic, Lidija
Villemagne, Victor L
Bourgeat, Pierrick
Burnham, Sam C
Cox, Timothy
Masters, Colin L
Rowe, Christopher C
Fripp, Jurgen
Doecke, James D
Laws, Simon M
Subject
AD onset
Alzheimer’s disease
Brain atrophy
Polygenic hazard score
Type of document
Journal Article
OrcId
0000-0002-8051-0558
0000-0002-5832-9875
0000-0003-3072-7940
0000-0003-3910-2453
DOI
10.1186/s12864-022-08617-2
Abstract
With a growing number of loci associated with late-onset (sporadic) Alzheimer's disease (AD), the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have shown promising results for identifying individuals at higher risk of developing AD, thereby facilitating the development of preventative and therapeutic strategies. A polygenic hazard score (PHS) has been proposed to quantify age-specific genetic risk for AD. In this study, we assessed the predictive power and transferability of this PHS in an independent cohort, to support its clinical utility. Using genotype and imaging data from 780 individuals enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, we investigated associations between the PHS and several AD-related traits, including 1) cross-sectional Aβ-amyloid (Aβ) deposition, 2) longitudinal brain atrophy, 3) longitudinal cognitive decline, 4) age of onset. Except in the cognitive domain, we obtained results that were consistent with previously published findings. The PHS was associated with increased Aβ burden, faster regional brain atrophy and an earlier age of onset. Overall, the results support the predictive power of a PHS, however, with only marginal improvement compared to apolipoprotein E alone.
Link
Citation
BMC genomics 2022; 23(1): 401
Jornal Title
BMC genomics

Files:

NameSizeformatDescriptionLink